The journey from an idea to a market-ready medicine is long, complex, and requires deep scientific insight at every stage. In today’s fast-paced pharmaceutical world, successful drug development depends on efficient, data-driven, and integrated Drug Discovery Services.
Jubilant Biosys, a global leader in drug discovery and development, partners with pharmaceutical and biotechnology companies to transform early-stage concepts into potential therapeutics. Through cutting-edge science, advanced technology platforms, and multidisciplinary expertise, Jubilant Biosys accelerates the path from target identification to candidate selection, ensuring innovation, speed, and reliability.
At Jubilant Biosys, we offer end-to-end drug discovery solutions that cover every aspect of preclinical research. Our services are designed to support clients across multiple therapeutic areas and drug modalities, ensuring seamless integration between chemistry, biology, pharmacology, and DMPK.
Our core Drug Discovery Services include:
· Target Identification and Validation
· Hit Identification and High-Throughput Screening (HTS)
· Hit-to-Lead and Lead Optimization
· Medicinal and Computational Chemistry
· In-Vitro and In-Vivo Biology Studies
· DMPK and Toxicology Evaluation
· Preclinical Candidate Selection
With world-class laboratories, global regulatory compliance, and a collaborative scientific environment, Jubilant Biosys helps clients make faster, more informed decisions in the drug discovery process.
Jubilant Biosys delivers deep domain expertise across several high-impact therapeutic areas — each with unique challenges and scientific opportunities. Our integrated approach ensures that every drug discovery program is tailored to the biological mechanisms, molecular targets, and clinical needs of each therapeutic field.
Cancer continues to be one of the most pressing global health challenges, demanding innovative and precise therapeutic strategies. At Jubilant Biosys, our Oncology Drug Discovery Services focus on designing and developing small molecules that target specific cancer pathways, mutations, and resistance mechanisms.
Our oncology capabilities include:
· Target validation for kinases, epigenetic regulators, and immune-oncology pathways.
· Screening assays to identify potent inhibitors.
· SAR (Structure-Activity Relationship) analysis for lead optimization.
· In-vitro and in-vivo efficacy models to assess tumor response.
By combining medicinal chemistry, cancer biology, and DMPK studies, Jubilant Biosys helps partners develop molecules with optimal pharmacokinetic and safety profiles. The result — faster development of targeted cancer therapies with improved efficacy and reduced toxicity.
The human brain remains one of the most complex frontiers in drug discovery. Disorders such as Alzheimer’s, Parkinson’s, epilepsy, and depression demand therapies that can cross the blood-brain barrier (BBB) and precisely modulate neurological targets.
Jubilant Biosys brings together deep neuroscience expertise and advanced discovery platforms to tackle these challenges. Our CNS Drug Discovery Services include:
· Design and synthesis of CNS-active compounds.
· BBB permeability studies and transporter assays.
· Neuropharmacological screening for receptor and enzyme interactions.
· In-vivo models for cognition, mood, and neurodegenerative disorders.
By integrating pharmacokinetic modeling, target engagement studies, and medicinal chemistry, Jubilant Biosys ensures that promising CNS compounds demonstrate optimal brain exposure and therapeutic relevance. Our scientists work collaboratively with clients to discover next-generation CNS drugs that improve neurological function and quality of life.
Chronic pain and inflammatory diseases such as arthritis, fibromyalgia, and autoimmune conditions remain major causes of disability worldwide. However, traditional pain medications often come with safety risks, tolerance, or dependency issues.
At Jubilant Biosys, our Pain and Inflammation Drug Discovery Services are focused on developing non-opioid, targeted therapies that deliver effective relief with reduced side effects.
Our capabilities include:
· Discovery of novel small-molecule inhibitors of inflammatory cytokines and enzymes (e.g., COX, TNF-α, IL-6).
· Ion channel modulation and neuroinflammation pathway targeting.
· In-vitro assays for receptor binding and enzyme inhibition.
· In-vivo pharmacology models for acute and chronic pain.
Through integrated chemistry, biology, and pharmacology efforts, Jubilant Biosys accelerates the development of safer analgesics and anti-inflammatory agents that address critical unmet medical needs.
Metabolic disorders such as Type 2 Diabetes, obesity, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD) are escalating global health concerns. Drug discovery in this domain requires a comprehensive understanding of complex biochemical pathways governing glucose, lipid, and energy metabolism.
Jubilant Biosys offers robust Drug Discovery Services for metabolic diseases, with expertise in:
· Target identification and validation for key metabolic enzymes and receptors.
· In-vitro and in-vivo screening for glucose-lowering and lipid-regulating effects.
· Medicinal chemistry optimization for potency and metabolic stability.
· Biomarker analysis and PK/PD correlation.
By leveraging systems biology, DMPK profiling, and translational pharmacology, Jubilant Biosys helps clients develop novel therapeutics that improve metabolic function, reduce complications, and enhance patient outcomes.
Choosing the right partner can make all the difference between a scientific idea and a clinical success story. Jubilant Biosys combines scientific innovation, technological excellence, and operational flexibility to deliver high-quality drug discovery solutions across the globe.
Key advantages of partnering with Jubilant Biosys include:
· Integrated discovery-to-development expertise across multiple disciplines.
· Experienced scientific teams with deep therapeutic knowledge.
· State-of-the-art laboratories equipped for high-throughput and high-content research.
· Flexible engagement models — FTE-based, project-based, or hybrid.
· Commitment to quality, data integrity, and regulatory compliance.
Our collaborative approach ensures that clients benefit from transparent communication, rapid decision-making, and scientifically validated outcomes at every stage of discovery.
At Jubilant Biosys, we believe that every great therapy begins with great science. Our Drug Discovery Services are designed to empower pharmaceutical and biotech innovators to transform ideas into life-changing medicines.
From groundbreaking oncology research and CNS therapeutics to innovative pain management and metabolic disease solutions, Jubilant Biosys delivers the expertise, infrastructure, and passion needed to drive discovery forward.
Partner with Jubilant Biosys — where innovation meets collaboration, and scientific discovery becomes therapeutic reality.